

Introducing the New Editor-in-Chief

You may recall that in the January issue of the journal I announced some big changes. This year marks the end of my 10-year term as Editor-in-Chief of *JNCCN*. It has been a remarkable journey. During this time, we refocused the journal content and saw a meteoric rise in submissions as well as a substantial increase in our impact factor, from 4.237 to 13.4. And as I step aside, don't worry about what will fill my time. I am taking a sabbatical to create a new Center for Early Detection and Interception in our Cancer Center at University of California, San Francisco. So, I won't be bored!

In addition, I firmly believe that 10 years is the right amount of time for any editor. Each of us only has so many fresh ideas, and once these are executed it can become easy to be complacent or reluctant to try something new. There is no doubt that *JNCCN* has improved. But I hope, along with the NCCN leadership team, that the journal can reach further to new levels. And that is the exciting task facing my successor. So, without further ado, let me introduce you to *JNCCN*'s new Editor-in-Chief, Daniel M. Geynisman, MD.

Dr. Geynisman is an Associate Professor in the Department of Hematology/Oncology and Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center. His particular research interest is in health outcomes and clinical trials development for genitourinary cancers. He is a member of ASCO and serves on ASCO's Ethics Committee and the Cancer.Net Editorial Board Psychosocial Oncology Advisory Panel.


He also has a long history with NCCN, including serving as a member on the NCCN Guidelines Panel for Testicular Cancer. He has reviewed abstracts for selection to be presented at the NCCN Annual Conference, served on various NCCN grant selection committees, and was himself a past recipient of NCCN research grants.

Dr. Geynisman is also no stranger to *JNCCN* or other medical publications. He has reviewed not only for *JNCCN* but also for a number of other respected publications, including *The New England Journal of Medicine*, *European Urology*, *Journal of Clinical Oncology*, *Cancer*, and *JCO Oncology Practice*. Since 2018, he has served as sole medical oncology editor for *Urologic Oncology: Seminars and Original Investigations*, and he has also authored more than 130 peer-reviewed publications.

And in closing, I have a bit of advice for Dr. Geynisman. Listen to your managing editorial team, as they have so much valuable experience, and to your Associate Editors, who will bring you new ideas and wise counsel. To quote Helen Keller, "Alone we can do so little; together we can do so much."



MARGARET TEMPERO, MD



DANIEL M. GEYNISMAN, MD

Thank You to Margaret Tempero From NCCN

Wui Jin Koh, MD, and Crystal S. Denlinger, MD, FACP

On behalf of NCCN, we'd like to thank Margaret Tempero, MD, for her decade of outstanding service as Editor-in-Chief of *JNCCN*. Since her tenure began in early 2014, the journal has continued to grow in stature and relevance to the oncology universe. This is clear from a more than 2-fold rise in submissions, excellent engagement of readership through both printed and online material, and the steady and consistent increase in impact factor, from 4.237 to 13.4! We appreciate her vision, dedication, expertise, and strong leadership for *JNCCN* and wish her great success in her new endeavors with the Center for Early Detection and Interception at UCSF.

J Natl Compr Canc Netw 2024;22(4):205
doi:10.6004/jnccn.2024.0025

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.